 A mutation that causes certain tyrosine kinases to be constitutively active has been associated with several cancers.Imatinib (brand names Gleevec and Glivec) is a drug able to bind the catalytic cleft of these tyrosine kinases, inhibiting its activity.Tyrosine kinase activity is also significantly involved in other events that are sometimes considered highly unfavorable.